BIOMAT Database Logo BIOMAT Database Logo

[Pyrrolo(3,2-d)pyrimidines as potential antitumor agents]. 1979

A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin

Antibacterial and antitumor properties of pyrrolo (3,2-d) pyrimidines having diverse substituents in the second, fourth and sixth position were investigated. Forty-four compounds were examined in vitro and 20 in vivo. A number of the derivatives were shown to inhibit the growth of M. tuberculosis H37Rv and lactic acid bacteria Lactobacillus casei 7469. Antibacterial activity depends on the character of the substituents in positions 2, 4 and 6. The tested compounds when administered per os to mice with sarcoma 180 (a solid variety) proved several dozen times less toxic than 6-mercaptopurine. Some of them inhibited the tumour growth up to 50%. The data obtained in vitro experiments indicate that the mechanism of the antitumour action of pyrrolo (3,2-d) yrimidines from that of 6-mercaptopurine.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Novel water-soluble substituted pyrrolo[3,2-d]pyrimidines: design, synthesis, and biological evaluation as antitubulin antitumor agents.
November 2012, Pharmaceutical research,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Novel synthesis of pyrrolo [2,3-d] pyrimidines bearing sulfonamide moieties as potential antitumor and radioprotective agents.
January 2006, Arzneimittel-Forschung,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Antiproliferative activities of halogenated pyrrolo[3,2-d]pyrimidines.
August 2015, Bioorganic & medicinal chemistry,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase (PNP) inhibitors as potential T-cell selective immunosuppressive agents.
January 1991, Advances in experimental medicine and biology,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Improved Syntheses of 3H,5H-Pyrrolo[3,2-d]pyrimidines.
October 1999, The Journal of organic chemistry,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
An Improved Synthesis of 7-Substituted Pyrrolo[3,2-d]pyrimidines.
November 1997, The Journal of organic chemistry,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.
November 2018, Bioorganic & medicinal chemistry,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Efficient solution-phase synthesis of 4,5,7-trisubstituted pyrrolo[3,2-d]pyrimidines.
January 2013, ACS combinatorial science,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
NEW APPROACHES TO THE SYNTHESIS OF 5H-PYRROLO(3,2-D)PYRIMIDINES.
May 1965, The Journal of organic chemistry,
A I Kravchenko, and V A Chernov, and L I Shcherbakova, and L N Filitis, and G N Pershin
Pyrrolo[3,2-h]quinazolines as photochemotherapeutic agents.
July 2011, ChemMedChem,
Copied contents to your clipboard!